Manager TitleAgeSince
Chief Executive Officer 67 24/05/2021
Chief Tech/Sci/R&D Officer - -
General Counsel - -
Change 5-day change 1-year change 3-year change Capi.($)
+500.00%-.--%-.--%-.--% 16.43L
-0.87%-2.29%+37.61%-2.73% 8.07TCr
-4.60%+7.09%+468.80%+27.55% 5.7TCr
-0.90%+3.51%-19.91%-35.69% 5.99TCr
+0.76%+3.53%+0.08%+36.18% 5.33TCr
+0.41%+1.84%+10.29%+171.67% 4.93TCr
+0.19%+3.34%+62.44%-16.23% 3.27TCr
-0.30%+0.41%+50.57%+100.03% 2.59TCr
-0.37%+4.88%+18.48%+209.06% 2.39TCr
+0.78%+0.47%+61.53%+123.40% 1.71TCr
Average +49.94%+2.23%+68.99%+61.32% 4TCr
Weighted average by Cap. -0.21%+2.10%+84.84%+46.94%

Financials

2016 2017
Net sales 33.39L 28.66L 26.83L 24.57L 46.28L 32Cr 46.41L 3.18Cr 1.24Cr 16Cr 1.25Cr 1.23Cr 53Cr 61.8L 53.05L 49.66L 45.48L 85.67L 59Cr 85.91L 5.88Cr 2.3Cr 30Cr 2.32Cr 2.27Cr 98Cr
Net income 14.02L 12.04L 11.27L 10.32L 19.44L 13Cr 19.5L 1.33Cr 52.17L 6.75Cr 52.65L 51.52L 22Cr 24.1L 20.68L 19.37L 17.73L 33.4L 23Cr 33.5L 2.29Cr 89.64L 12Cr 90.47L 88.52L 38Cr
Net Debt - -
Logo Stemcell Holdings, Inc.
Stemcell Holdings, Inc. is engaged in the regenerative medicine-related business, which provides technical assistance to the culturing, storing and delivery of stem cells, administrative and consulting services to clinics. The Company provides two options for stem cell regenerative therapy: autologous adipose derived mesenchymal stem cells (ADMSC) and natural killer cells (NK). The Company provides coordination services to facilitate its stem cell culturing business. Its coordination services include the introduction of patients to clinics, arranging patients’ schedules, and translating between patients and clinics. The Company offers Internet marketing services by providing search engine optimization for clinics. It also offers property and equipment rental services. The Company operates through its wholly owned subsidiary, Stemcell Co., Ltd.
Employees
-
  1. Stock Market
  2. Stocks
  3. STMM Stock